IPM.ai transforms data into insights that uncover the ideal patient and their healthcare ecosystem so that life sciences companies can accelerate the commercialization of precision therapies for specialty and rare diseases quicker, with less risk. IPM.ai’s Insights as a Service (IaaS) platform optimizes drug development, clinical study, product launch, and commercial operations by utilizing AI and ML in conjunction with a data universe of de-identified patient journeys and anonymized social determinants of health signals.
IPM.ai's Product Videos
Compete with IPM.ai?
Ensure that your company and products are accurately represented on our platform.
IPM.ai's Products & Differentiators
IPM System of Insight
Uncovers the ideal patient population, their diagnostic and treatment journey and their healthcare ecosystem
Expert Collections containing IPM.ai
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
IPM.ai is included in 3 Expert Collections, including Artificial Intelligence.
This collection includes startups selling AI SaaS, using AI algorithms to develop their core products, and those developing hardware to support AI workloads.
Technologies, platforms, and systems that engage consumers for lifestyle, wellness, or health-related purposes; capture, store, or transmit health data; and/or support life science and clinical operations. (DiME, DTA, HealthXL, & NODE.Health)
Value-Based Care & Population Health
The VBC & Population Health collection includes companies that enable and deliver care models that address the health needs for defining populations along the continuum of care, including in the community setting, through participation, engagement, and targeted interventions.
Latest IPM.ai News
Mar 8, 2022
Recognition underscores IPM.ai's AI-powered approach to finding undiagnosed and misdiagnosed patients suffering from specialty and rare diseases March 08, 2022 09:00 AM Eastern Standard Time SAN FRANCISCO--( BUSINESS WIRE )--IPM.ai, part of Real Chemistry and a leader in uncovering undiagnosed and misdiagnosed patients for specialty and rare disease via machine learning and artificial intelligence, today announced it has been named by Fast Company as one of the World's Most Innovative Companies for 2022. IPM.ai was named #2 in the Data Science category in recognition of its transformational approach to inform and accelerate the development, clinical study and commercialization of precision medicine by health care and life sciences companies. Each year, Fast Company editors and reporters work to identify and recognize organizations transforming industries, shaping society, and moving the world forward. Since its inception in 2008, its World’s Most Innovative Companies list has been the definitive source for identifying innovative companies moving the world forward. "We are honored and privileged to be named as one of the world’s Most Innovative Companies in Data Science by Fast Company," said IPM.ai co-founder and president Ron Elwell. "Rare diseases pose distinct challenges for drug development, particularly at critical decision points in the product lifecycle. With small and largely undiagnosed populations, traditional approaches to patient finding for these conditions are reliant on previously diagnosed patients and typically result in highly inaccurate outcomes. Our approach uncovers patients with the highest likelihood of disease manifestation, whether diagnosed, undiagnosed or misdiagnosed, leading to earlier disease interception and optimal patient outcomes faster and with less risk.” IPM.ai's HIPAA-compliant system of insight applies artificial intelligence and machine learning against a tokenized, real world data universe of more than 300 million de-identified patient journeys, 65 billion anonymous social determinants of health signals and first-party sources of any type and scale such as genetic testing, laboratory research and epidemiological asessments. By uncovering patients who present with a rare disease using privacy-safe real world data, IPM.ai creates the ideal patient definition, models undiagnosed and misdiagnosed lookalike patients and maps patient treatment journeys to associated primary care physicians and specialists. This augmented intelligence approach can be applied across the product lifecycle, from rapidly assessing the size of a market for an orphan drug to uncovering patients with the highest propensity for successful clinical study screening and those most likely to begin a newly launched or in-market therapy. “Patients with rare diseases face seemingly insurmountable odds,” added Real Chemistry CEO Shankar Naryanan. “They are undiagnosed or misdiagnosed for six years on average, and consult more than seven physicians during their diagnostic and treatment odyssey, resulting in low quality of life, extreme burden on caregivers and financial hardship. By uncovering these patients and their associated health care providers, IPM.ai helps connect the precision medicine pioneers with novel treatments to those most in need earlier, transforming the lives of patients and their loved ones.” About IPM.ai and Real Chemistry IPM.ai, part of Real Chemistry ( www.ipm.ai ), transforms real-world data into real-world insights that uncover the ideal patient and their healthcare ecosystem so that life sciences companies can accelerate the successful development, clinical study and commercialization of critical therapies for specialty and rare diseases. IPM.ai’s Insights as a Service (IaaS) platform optimizes drug development, clinical study, product launch and commercial operations by utilizing granular-level longitudinal analytics, artificial intelligence and machine learning in conjunction with a real-world data universe of over 300 million de-identified patient journeys and 65 billion anonymized social determinants of health signals. We’re making the promise of precision medicine an analytical reality. And we are just getting started. Real Chemistry is making the world a healthier place by empowering patients to access the right treatment at the right time. We leverage the best data-driven, tech-enabled and digital solutions to deliver communications, engagement, activation and value across a full range of diverse health care stakeholders — patients, payors, providers, caregivers and regulators. For more information, please visit at www.pm.ai and connect with us on LinkedIn or Twitter Contacts
IPM.ai Frequently Asked Questions (FAQ)
When was IPM.ai founded?
IPM.ai was founded in 2017.
Where is IPM.ai's headquarters?
IPM.ai's headquarters is located at 125 Cambridgepark Drive, Cambridge.
What is IPM.ai's latest funding round?
IPM.ai's latest funding round is Acquired.
Who are the investors of IPM.ai?
Investors of IPM.ai include W2O Group.
Who are IPM.ai's competitors?
Competitors of IPM.ai include Clarify Health and 5 more.
What products does IPM.ai offer?
IPM.ai's products include IPM System of Insight.
Compare IPM.ai to Competitors
Evidation measures health in everyday life and enables anyone to participate in research and health programs. Evidation is a two-sided platform that connects individuals and enterprises. On the consumer side, the company assists individuals to participate in research including testing of digital health programs. On the enterprise side, Evidation provides biopharma, med-tech, big tech, academic institutions, professional societies, and government partners the ability to: generate evidence; and design, test, and deploy programs that motivate evidence-based action.
Nuna is a healthcare technology company that seeks to help make high-quality healthcare affordable and accessible for everyone. The company does this by building data solutions for healthcare payers and providers to measure and improve their cost and quality outcomes.
QantEv optimizes provider networks for health insurers. Its platform offers an AI-based data analytics solution designed to improve health insurers’ operations, including health data management, automation triage, and resolution of simple claims. The firm serves clients in the healthcare sector. It was founded in 2019 and is based in Paris, France.
H1 is a platform for global HCP, clinical, scientific, and research information. The H1 Connect platform democratizes access to HCP knowledge and insights for life sciences, academic medical institutions, health systems, and payors. H1 Connect fuels a robust product suite that helps customers discover and engage industry experts, drive equitable research, access science, and accelerate commercial success with healthcare professional data. The company's clients include life sciences companies, academic medical institutions, health systems, and payors. H1 was founded in 2017 and is based in New York, New York.
Aetion delivers real-world evidence for life sciences companies, payers, at-risk providers, and regulatory agencies. The Aetion Evidence Platform analyzes data from the real world to produce rapid and scientifically validated answers on treatments, costs, and outcomes. Aetion informs health care's most critical decisions - what works best, for whom, and when - to guide treatment development, commercialization, and payment values into health care's modern era.
PurpleLab is a healthtech company focused on driving decisive actions based on precise insights from real-world data. It develops HealthNexus, a no-code analytics platform that empowers life science, payers, providers, and other healthcare stakeholders to develop real-world evidence (RWE) that therapeutics or clinical strategies are performing and leading to savings in lives and costs. The company semantically harmonizes critical events and relationships between data types at scale, making them analytics-ready. With integrated insights on de-identified patients, providers, and payers, clients receive ongoing objective, quantitative, predictive, and ad hoc real-world evidence to meet their business objectives. These include diagnosis, medications, procedures, measurements, observations, and indications. PurpleLab was founded in 2016 and is based in Wilmington, Delaware.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.